Cargando…
长春瑞滨联合异环磷酰胺三线以后治疗晚期非小细胞肺癌的疗效和不良反应
BACKGROUND AND OBJECTIVE: Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) should be treated with first-line and second-line chemotherapy or target therapy according to the lung cancer guidelines. However, no recommended treatments are available after failure to these...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999901/ https://www.ncbi.nlm.nih.gov/pubmed/26104891 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.06.04 |
Ejemplares similares
-
长春瑞滨联合奥沙利铂对比长春瑞滨联合顺铂治疗中晚期非小细胞肺癌的系统评价
Publicado: (2010) -
口服长春瑞滨节拍化疗治疗晚期多线治疗失败的非小细胞肺癌的临床观察
Publicado: (2017) -
基于三甲基苯磺酰羟胺消除反应的氧连接氮乙酰葡萄糖胺修饰肽段的精准鉴定
por: GUO, Zhixin, et al.
Publicado: (2021) -
氟达拉滨和环磷酰胺联合利妥昔单抗(FCR方案)一线治疗慢性淋巴细胞白血病43例临床分析
Publicado: (2021) -
沙利度胺联合环磷酰胺和地塞米松治疗症状性华氏巨球蛋白血症的前瞻性临床研究
Publicado: (2023)